D. Facklam
About
In The Last Decade
D. Facklam
16 papers receiving 867 citations
Peers
Comparison fields: 5 of 66
- Infectious Diseases 767
- Epidemiology 641
- Small Animals 175
- Pharmacology 139
- Pulmonary and Respiratory Medicine 104
Countries citing papers authored by D. Facklam
This map shows the geographic impact of D. Facklam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Facklam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Facklam more than expected).
Fields of papers citing papers by D. Facklam
This network shows the impact of papers produced by D. Facklam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Facklam. The network helps show where D. Facklam may publish in the future.
Co-authorship network of co-authors of D. Facklam
This figure shows the co-authorship network connecting the top 25 collaborators of D. Facklam. A scholar is included among the top collaborators of D. Facklam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Facklam. D. Facklam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 75 | |
| 3 | 209 | |
| 4 | 6 | |
| 5 | 122 | |
| 6 | 176 | |
| 7 | 145 | |
| 8 | 60 | |
| 9 | 32 | |
| 10 | 6 | |
| 11 | 3 | |
| 12 | Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study. | 16 |
| 13 | FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. | 25 |
| 14 | 13 | |
| 15 | 2 | |
| 16 | 4 | |
| 17 | Is post-marketing drug surveillance possible in the family practice setting? A collaborative study. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.